Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
09/2003
09/18/2003US20030176381 Hyaluronic acid in the treatment of cancer
09/18/2003US20030176366 Topical application of ascorbic acid compounds for augmenting the synthesis of epidermal ceramides
09/18/2003US20030176365 To improve cerebral function
09/18/2003US20030176363 For therapy of T lymphocyte mediated inflammatory diseases in animals and man
09/18/2003US20030176359 Administration of a thiol-based chemoprotectant compound
09/18/2003US20030176351 Peptides and peptide analogues designed from a diabetes-associated autoantigen, and methods for their use in the treatment and prevention of diabetes
09/18/2003US20030176346 Using substances that activate the CNTF (ciliary neurotrophic factor) receptor for the preparation of pharmaceutical formulations for therapy of obesity and diseases associated therewith, for example diabetes
09/18/2003US20030176336 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
09/18/2003US20030176324 Derivatives of water insoluble drugs which exhibit good activity and water solubility
09/18/2003US20030176319 N4-acylcytosine-1,3- dioxolane nucleosides for treatment of viral infections
09/18/2003US20030176318 Administering a therapeutically effective amount of a temporary p53 inhibitor to an individual suffering from the disease or condition
09/18/2003US20030176317 Stabilization of hypoxia inducible factor (HIF) alpha
09/18/2003US20030176315 Contacting latency-associated peptide- beta 1 (LAP- beta 1) or a functional variant thereof and integrin alpha v beta 3 or a functional variant thereof with test product under conditions that, in absence of test product, would permit interaction
09/18/2003US20030175962 Gene encoding b protein
09/18/2003US20030175934 Controlling cell differentiation, cell proliferation; anticancer agents
09/18/2003US20030175920 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
09/18/2003US20030175885 Peptides and derivatives thereof showing cell attachment, spreading and detachment activity
09/18/2003US20030175881 Nucleic acids encoding (poly) peptides having chips activity
09/18/2003US20030175855 Human sdf-5 protein and compositions
09/18/2003US20030175849 Identifying compounds for treating vision defects associated with intraocular pressure
09/18/2003US20030175823 Method of screening remedy for heart failures
09/18/2003US20030175775 Ligand for G-protein coupled receptor GPR43 and uses thereof
09/18/2003US20030175766 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
09/18/2003US20030175374 Oxidation resistance; anticancer agents, antiinflammatory agents; sunscreen agents
09/18/2003US20030175351 Pharmaceutical composition for oral use with improved absorption
09/18/2003US20030175334 Phospholipid bodies and use thereof in medical treatment
09/18/2003US20030175297 Cancer vaccines
09/18/2003US20030175289 TIE ligands
09/18/2003US20030175288 Polypeptides used for induction of cytotoxic T lymphocytes or activation of human leukocyte antigens (HLA), administered as anticarcinogenic vaccines; immunology
09/18/2003US20030175276 Monoclonal antibodies used as antagonists vascular endothelial growth factors (VEGF); angiogenesis inhibitors; antitumor agents
09/18/2003US20030175274 Polynucleotides codes for antibodies having amino acid sequences selected from complementary determining regions of variable peptides or single chain fragments, used as anticarcinogenic agents
09/18/2003US20030175245 Replication deficient adenoviral TNF vector
09/18/2003US20030175209 Image diagnosis of a brain tumor, renal carcinoma; tumor treatment therapies, immunotherapy
09/18/2003US20030175205 Comprising a radioactive materials for detecting and/or quantifying diseases or conditions associated with cancer, infections, inflammation; a 2-propane carboxylic ester with a attached phosphatidic acid group
09/18/2003DE20121877U1 Module for suppressing leukocyte activity, useful e.g. in association with heart-lung machines, comprises a carrier linked to a ligand specific for the leukocyte receptor
09/18/2003CA2671976A1 Methods of inducing terminal differentiation
09/18/2003CA2482191A1 Spiro compounds with npy antagonistic activity
09/18/2003CA2479071A1 Process for producing optically active sulfoxide derivative
09/18/2003CA2479056A1 Protein sustaining undifferentiated stem cells as such
09/18/2003CA2479036A1 Aryl substituted pyrimidines and the use thereof
09/18/2003CA2479016A1 Quinazoline compounds useful in therapy
09/18/2003CA2478963A1 Method of generating molecule-function network
09/18/2003CA2478958A1 Use of proton pump inhibitors for the treatment of airway disorders
09/18/2003CA2478948A1 5-}2-hydroxy-3-`1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}-phtalide and related compounds with progesterone receptor modulating a ctivity for use in fertility control and hormone replacement therapy
09/18/2003CA2478945A1 Cyclic amides
09/18/2003CA2478942A1 An optically active pyridine derivative and a medicament containing the same
09/18/2003CA2478921A1 Novel chalcone derivatives and uses thereof
09/18/2003CA2478897A1 Compounds capable of inhibiting immunocyte-related allergic immune reactions
09/18/2003CA2478827A1 Remedies for sex hormone-dependent disease
09/18/2003CA2478706A1 Oxo-azabicyclic compounds
09/18/2003CA2478701A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino) pyrimidine with cdk inhibitory activity
09/18/2003CA2478479A1 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phagebeta protein, or hydroxyurea
09/18/2003CA2478412A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same
09/18/2003CA2478369A1 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
09/18/2003CA2478338A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers
09/18/2003CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
09/18/2003CA2478276A1 Azepane derivatives and their use as atk1 inhibitors
09/18/2003CA2478239A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
09/18/2003CA2478169A1 Human antibodies specific to kdr and uses thereof
09/18/2003CA2478087A1 Microtubule stabilizing compounds
09/18/2003CA2478082A1 Uses of monoclonal antibody 8h9
09/18/2003CA2478065A1 Macrocyclic compounds useful as pharmaceuticals
09/18/2003CA2477984A1 Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
09/18/2003CA2477973A1 Methods for alzheimer's disease treatment and cognitive enhancement
09/18/2003CA2477949A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation
09/18/2003CA2476938A1 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43
09/18/2003CA2476183A1 Treatment of type i diabetes mellitus using growth hormone antagonist
09/18/2003CA2472782A1 Materials containing multiple layers of vesicles
09/18/2003CA2472119A1 Screening method for orthopoxvirus antivirals
09/17/2003EP1344780A1 Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
09/17/2003EP1344779A1 Azolo-pyrimidines
09/17/2003EP1344777A1 Imidazole derivatives, process for their preparation and their use
09/17/2003EP1344536A1 Method of regulating the activity of expression product of gene transferred into living body
09/17/2003EP1344535A2 Combined angiotensin II antagonists and adrenaline receptor blockers for treatment of glaucoma
09/17/2003EP1344534A2 Combined angiotensin II antagonists and carbonic anhydrase inhibitors for treatment of glaucoma
09/17/2003EP1344530A1 Interleukin-18 inducing agent
09/17/2003EP1344528A1 External skin preparations and process for producing the same
09/17/2003EP1344525A1 Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
09/17/2003EP1344522A1 Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
09/17/2003EP1343913A2 Antisense modulation of src-2 expression
09/17/2003EP1343900A2 Oxidoreductases
09/17/2003EP1343896A1 Small acid-soluble spore protein and uses thereof
09/17/2003EP1343890A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
09/17/2003EP1343887A2 Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
09/17/2003EP1343876A2 Modulators of activity of g-protein-coupled receptor kinases
09/17/2003EP1343822A2 Means for the diagnosis and therapy of ctcl
09/17/2003EP1343818A1 Modified tachykinin receptors
09/17/2003EP1343807A2 Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
09/17/2003EP1343804A1 14(15)-unsaturated 15- and/or 16- substituted androgens with mixed androgen-progestational profile
09/17/2003EP1343803A2 2-substituted estrogens as antiangiogenic agents
09/17/2003EP1343791A2 Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists
09/17/2003EP1343789A1 Tricyclic derivatives of indole with antiangiogenic activity
09/17/2003EP1343786A1 Novel pyridine-substituted pyrazolopyridine derivatives
09/17/2003EP1343784A2 Urea substituted imidazoquinoline ethers
09/17/2003EP1343783A2 Substituted imidazopyridines
09/17/2003EP1343781A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
09/17/2003EP1343778A2 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
09/17/2003EP1343775A2 Piperazine derivatives
09/17/2003EP1343774A1 1,1-dioxo-2h-1, 2-benzothiazine-3-carboxamide derivatives, method for preparing same and pharmaceutical compositions comprising same
09/17/2003EP1343773A1 Thiazole derivatives for traeing ppar related disorders
1 ... 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 ... 1564